Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Early-onset Alzheimer's patients accumulate symptoms years before diagnosis (opens in a new tab)

news-medical.net · 2026-10-09

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. 2 other points were not covered by the paper.

  • 3 supported
  • 2 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two of seven claims overstate the study. Three of seven check out. Two claims the study doesn't address.

  • 3 supported
  • 2 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7OverstatedPeople who develop Alzheimer’s disease before age 65 experience a growing range of health problems and increasing use of healthcare services years before diagnosis.View evidenceHide evidence

As statedyears before diagnosis

Why this verdict

The abstract-level profile supports that future EOAD cases had more register-recorded comorbidities in the 1–5 years before diagnosis and one disease category differing at 6–10 years. It also supports increased health-care use near diagnosis. However, the headline-level framing says health-care use increased 'years before diagnosis,' while the abstract-supported utilization finding is specifically a marked increase from the year immediately before diagnosis. The headline therefore outruns the abstract evidence on the timing of utilization.

1

Study evidence

Between 1–5 years before diagnosis, EOAD patients had higher prevalence of vertigo (5.9% vs. 2.1%, p < 0.001), depression (5.7% vs. 2.3%, p < 0.001), headache (4.9% vs. 1.6%, p < 0.001), delirium (1.5% vs. 0.1%, p < 0.001), brain injuries (2.9% vs. 0.9%, p = 0.002), thyroid disorders (2.5% vs. 0.8%, p = 0.008), alcohol-related disorders (3.4% vs. 1.4%, p = 0.009), epilepsy (2.2% vs. 0.7%, p = 0.009), strokes (4.4% vs. 2.0%, p = 0.008), and otorhinolaryngologic diseases (5.2% vs. 2.9%, p = 0.027).Reported group prevalences and p-values as listed in text (see above).

“This population-based case-control study included 407 EOAD patients diagnosed at two Finnish university hospitals (2010-2021), and 4035 age- and sex-matched controls.”
2

Study evidence

Register-recorded health-care use increased markedly in the year immediately before EOAD diagnosis among future EOAD cases compared with matched controls.

“Prior diagnoses and health-care visits were obtained from nationwide registers.”
Claim 2 of 7OverstatedHealthcare utilisation increased markedly during the five years leading up to diagnosis, with the steepest increase in the final year before Alzheimer’s disease was diagnosed.View evidenceHide evidence

As statedduring the five years leading up to diagnosis; steepest in the final year

Why this verdict

The profile supports a marked increase in register-recorded health-care use near diagnosis, specifically from the year immediately before EOAD diagnosis. It does not support, at abstract depth, a marked increase throughout the full five-year period or the specific statement that the steepest increase occurred in the final year. The direction is supported, but the timing and trajectory detail are stronger than the supplied evidence.

1

Study evidence

Register-recorded health-care use increased markedly in the year immediately before EOAD diagnosis among future EOAD cases compared with matched controls.

“Prior diagnoses and health-care visits were obtained from nationwide registers.”
Claim 3 of 7Not coveredTinnitus and hearing loss were already more common six to ten years before diagnosis.View evidenceHide evidence

As statedsix to ten years before diagnosis

Why this verdict

The abstract-level profile says only otorhinolaryngologic diseases differed in the 6–10 year window. It does not specify tinnitus or hearing loss as the conditions driving that category. The claim may be consistent with fuller paper details, but it is not verifiable from the supplied abstract-depth profile.

1

Study evidence

Between 1–5 years before diagnosis, EOAD patients had higher prevalence of vertigo (5.9% vs. 2.1%, p < 0.001), depression (5.7% vs. 2.3%, p < 0.001), headache (4.9% vs. 1.6%, p < 0.001), delirium (1.5% vs. 0.1%, p < 0.001), brain injuries (2.9% vs. 0.9%, p = 0.002), thyroid disorders (2.5% vs. 0.8%, p = 0.008), alcohol-related disorders (3.4% vs. 1.4%, p = 0.009), epilepsy (2.2% vs. 0.7%, p = 0.009), strokes (4.4% vs. 2.0%, p = 0.008), and otorhinolaryngologic diseases (5.2% vs. 2.9%, p = 0.027).Reported group prevalences and p-values as listed in text (see above).

“This population-based case-control study included 407 EOAD patients diagnosed at two Finnish university hospitals (2010-2021), and 4035 age- and sex-matched controls.”
Claim 4 of 7Not coveredThe article says the findings suggest early-onset Alzheimer’s disease may involve mechanisms that differ, at least in part, from those underlying late-onset Alzheimer’s disease, and that diagnosis in working-age adults is often delayed by several years after first symptoms appear.View evidenceHide evidence

As statedseveral years

Why this verdict

The profile supports differences from common late-onset cardiovascular risk expectations only indirectly, through the lack of hypertension and dyslipidemia differences. It does not provide abstract-level evidence for different underlying mechanisms from late-onset Alzheimer’s disease, nor does it document diagnostic delay of several years after first symptoms. These may be discussion-context claims, but they are not verifiable from the supplied abstract-depth profile.

1

Study evidence

Between 1–5 years before diagnosis, EOAD patients had higher prevalence of vertigo (5.9% vs. 2.1%, p < 0.001), depression (5.7% vs. 2.3%, p < 0.001), headache (4.9% vs. 1.6%, p < 0.001), delirium (1.5% vs. 0.1%, p < 0.001), brain injuries (2.9% vs. 0.9%, p = 0.002), thyroid disorders (2.5% vs. 0.8%, p = 0.008), alcohol-related disorders (3.4% vs. 1.4%, p = 0.009), epilepsy (2.2% vs. 0.7%, p = 0.009), strokes (4.4% vs. 2.0%, p = 0.008), and otorhinolaryngologic diseases (5.2% vs. 2.9%, p = 0.027).Reported group prevalences and p-values as listed in text (see above).

“This population-based case-control study included 407 EOAD patients diagnosed at two Finnish university hospitals (2010-2021), and 4035 age- and sex-matched controls.”
Claim 5 of 7SupportedA University of Oulu and University of Eastern Finland study found that people with early-onset Alzheimer’s disease accumulated many health problems, especially during the five years before diagnosis, including depression, dizziness, headaches, traumatic brain injuries, epilepsy, cerebrovascular disorders, thyroid diseases, and problems related to heavy alcohol use.View evidenceHide evidence

As statedparticularly during the five years preceding diagnosis

Why this verdict

The profile supports higher prevalence 1–5 years before diagnosis for depression, vertigo/dizziness, headache, brain injuries, thyroid disorders, alcohol-related disorders, epilepsy, strokes/cerebrovascular disorders, and other diagnoses. The claim is framed associationally and matches the abstract-level finding that many health problems accumulated particularly in the five years before diagnosis.

1

Study evidence

Between 1–5 years before diagnosis, EOAD patients had higher prevalence of vertigo (5.9% vs. 2.1%, p < 0.001), depression (5.7% vs. 2.3%, p < 0.001), headache (4.9% vs. 1.6%, p < 0.001), delirium (1.5% vs. 0.1%, p < 0.001), brain injuries (2.9% vs. 0.9%, p = 0.002), thyroid disorders (2.5% vs. 0.8%, p = 0.008), alcohol-related disorders (3.4% vs. 1.4%, p = 0.009), epilepsy (2.2% vs. 0.7%, p = 0.009), strokes (4.4% vs. 2.0%, p = 0.008), and otorhinolaryngologic diseases (5.2% vs. 2.9%, p = 0.027).Reported group prevalences and p-values as listed in text (see above).

“This population-based case-control study included 407 EOAD patients diagnosed at two Finnish university hospitals (2010-2021), and 4035 age- and sex-matched controls.”
Claim 6 of 7SupportedHigh blood pressure and hyperlipidemia were not more common among people with early-onset Alzheimer’s disease than among age- and sex-matched controls without neurodegenerative disease.View evidenceHide evidence

Why this verdict

The profile explicitly reports that hypertension and dyslipidemia showed no between-group differences across the assessed pre-diagnosis windows in EOAD cases versus age- and sex-matched controls.

1

Study evidence

Between 1–5 years before diagnosis, EOAD patients had higher prevalence of vertigo (5.9% vs. 2.1%, p < 0.001), depression (5.7% vs. 2.3%, p < 0.001), headache (4.9% vs. 1.6%, p < 0.001), delirium (1.5% vs. 0.1%, p < 0.001), brain injuries (2.9% vs. 0.9%, p = 0.002), thyroid disorders (2.5% vs. 0.8%, p = 0.008), alcohol-related disorders (3.4% vs. 1.4%, p = 0.009), epilepsy (2.2% vs. 0.7%, p = 0.009), strokes (4.4% vs. 2.0%, p = 0.008), and otorhinolaryngologic diseases (5.2% vs. 2.9%, p = 0.027).Reported group prevalences and p-values as listed in text (see above).

“This population-based case-control study included 407 EOAD patients diagnosed at two Finnish university hospitals (2010-2021), and 4035 age- and sex-matched controls.”
Claim 7 of 7SupportedThe study found no significant differences in morbidity 11 to 15 years before diagnosis, suggesting that identifiable changes begin to emerge mainly closer to disease onset.View evidenceHide evidence

As stated11 to 15 years before diagnosis

Why this verdict

The profile reports no between-group differences in the 11–15 year pre-diagnosis window. The story's conclusion that identifiable differences emerge mainly closer to diagnosis is hedged and consistent with the reported 1–5 year differences and limited 6–10 year difference.

1

Study evidence

Between 1–5 years before diagnosis, EOAD patients had higher prevalence of vertigo (5.9% vs. 2.1%, p < 0.001), depression (5.7% vs. 2.3%, p < 0.001), headache (4.9% vs. 1.6%, p < 0.001), delirium (1.5% vs. 0.1%, p < 0.001), brain injuries (2.9% vs. 0.9%, p = 0.002), thyroid disorders (2.5% vs. 0.8%, p = 0.008), alcohol-related disorders (3.4% vs. 1.4%, p = 0.009), epilepsy (2.2% vs. 0.7%, p = 0.009), strokes (4.4% vs. 2.0%, p = 0.008), and otorhinolaryngologic diseases (5.2% vs. 2.9%, p = 0.027).Reported group prevalences and p-values as listed in text (see above).

“This population-based case-control study included 407 EOAD patients diagnosed at two Finnish university hospitals (2010-2021), and 4035 age- and sex-matched controls.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The utilization evidence at abstract depth lacks quantitative estimates, confidence intervals, visit-type definitions, and details on adjustment for confounders or sensitivity analyses.

    The story's caveats mention register data, matched controls, diagnostic difficulty, and that no single disease or symptom predicts Alzheimer’s disease. It does not acknowledge the abstract-level limitations around unquantified utilization results, unclear visit definitions, or unspecified adjustment, which are relevant to interpreting the strength and precision of utilization claims.

    From Population-based matched case-control with nationwide register linkage

6 things the story did carry across
  • The paper is a Finnish population-based matched case-control register study of 407 EOAD cases diagnosed at two university hospitals from 2010–2021 and 4035 age- and sex-matched controls.
  • The main comorbidity finding is that multiple diagnoses were more prevalent among future EOAD cases in the 1–5 years before diagnosis, including vertigo, depression, headache, delirium, brain injuries, thyroid disorders, alcohol-related disorders, epilepsy, strokes, and otorhinolaryngologic diseases.
  • In the 6–10 year window, the abstract-level profile reports only otorhinolaryngologic diseases as differing between groups; no differences were seen 11–15 years before diagnosis.
  • Hypertension and dyslipidemia showed no between-group differences in the assessed pre-diagnosis windows.
  • Health-care use increased markedly from the year immediately before EOAD diagnosis, with no abstract-level quantitative estimate or detailed utilization definition supplied.
  • The findings are observational register-based associations and should not be interpreted as individual-level prediction or proof that the listed conditions cause EOAD.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataDetermine whether specific comorbidities/diagnoses differ between individuals later diagnosed with early-onset Alzheimer’s disease (EOAD) and matched controls over multiple pre-diagnosis time windows (up to 15 years).population-based matched case-controlExpand

In plain English

Population-based, register-linked matched case-control study (407 EOAD cases, 4035 age- and sex-matched controls) comparing prevalence of prior diagnoses across 1–5, 6–10, and 11–15 year pre-diagnosis windows. Multiple neuropsychiatric and neurological comorbidities and increased health-care use were more common in EOAD cases in the 1–5 years before diagnosis; fewer differences were evident earlier.

Key findings

  • Between 1–5 years before diagnosis, EOAD patients had higher prevalence of vertigo (5.9% vs. 2.1%, p < 0.001), depression (5.7% vs. 2.3%, p < 0.001), headache (4.9% vs. 1.6%, p < 0.001), delirium (1.5% vs. 0.1%, p < 0.001), brain injuries (2.9% vs. 0.9%, p = 0.002), thyroid disorders (2.5% vs. 0.8%, p = 0.008), alcohol-related disorders (3.4% vs. 1.4%, p = 0.009), epilepsy (2.2% vs. 0.7%, p = 0.009), strokes (4.4% vs. 2.0%, p = 0.008), and otorhinolaryngologic diseases (5.2% vs. 2.9%, p = 0.027).Reported group prevalences and p-values as listed in text (see above).
  • Only otorhinolaryngologic diseases differed in the 6–10 year window (4.7% vs. 2.1%, p = 0.036).4.7% in cases vs 2.1% in controls, p = 0.036.
“This population-based case-control study included 407 EOAD patients diagnosed at two Finnish university hospitals (2010-2021), and 4035 age- and sex-matched controls.”
2secondary dataDetermine whether patterns of health-care use (health-care visits/utilization) differ between future EOAD cases and matched controls during the 15 years preceding diagnosis, including near-diagnosis escalation.Population-based matched case-control with nationwide register linkageExpand

In plain English

In a Finnish population-based matched case-control study using nationwide registers (407 EOAD cases, 4035 age- and sex-matched controls), health-care utilization measured from registers over the 15 years before diagnosis showed a marked increase in health-care use beginning in the year immediately before EOAD diagnosis.

Key findings

  • Register-recorded health-care use increased markedly in the year immediately before EOAD diagnosis among future EOAD cases compared with matched controls.
“Prior diagnoses and health-care visits were obtained from nationwide registers.”
What this piece can’t prove
  • Abstract does not provide quantitative estimates, confidence intervals, or effect sizes for utilization differences.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 40 candidate papers

Candidate

Vascular Dementia: Cerebrovascular Injury, Clinical Syndromes, Neuroimaging, and Interaction with Alzheimer Pathology

World Family Medicine Journal /Middle East Journal of Family Medicine · 2026 · Crossref

Source (opens in a new tab)

And 34 more candidates considered.